CanSino Biologics, Inc. is a pharmaceutical company located in China that specializes in researching, developing, and distributing vaccine products for human use. Some of its products include Menhycia, Convidecia, and Ad5-EBOV. With an ESG score of 25.5, CanSino Biologics is considered a medium-risk company. The majority of its revenue comes from operations in China and overseas markets.